KCM
ABBV icon

Karp Capital Management’s AbbVie ABBV Stock Holding History

Karp Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-550
Closed -$30K – 94
2015
Q3 		$30K Buy
+550
New +$35.8K 0.02% 207

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Karp Capital Management's ABBV Position: Q4 2015 in Review

Karp Capital Management sold out of AbbVie (ABBV) in Q4 2015, closing a stake of 550 shares — an estimated $30K sold.

Karp Capital Management first reported a position in ABBV in Q3 2015 and held it in 1 quarter. The position peaked at $30K in Q3 2015. 1,635 funds tracked by Wall St. Rank hold ABBV as of Q4 2015.

  • Karp Capital Management reported no remaining AbbVie position as of Q4 2015 after selling out during the quarter.
  • Karp Capital Management sold 550 AbbVie shares in Q4 2015, an estimated $30K.
  • Karp Capital Management first reported a position in AbbVie in Q3 2015 and held it in 1 quarter.
  • Karp Capital Management's AbbVie position peaked at $30K in Q3 2015.
  • 1,635 funds tracked by Wall St. Rank held AbbVie as of Q4 2015.

Based on Karp Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.